- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00438581
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma (Zevalin)
February 26, 2007 updated by: McGill University
Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
This aim of this study to evaluate the safety and efficacy of combining a single course of Yttrium 90 Ibritumomab Tiuxetan, a radiolabeled monoclonal antibody ( Zevalin ), with high-dose BEAM chemotherapy and autologous peripheral stem cell transplantation in patients with relapsed, refractory, or transformed Non-Hodgkin's lymphoma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Relapse rates after chemotherapy for relapsed, refractory or transformed Non-Hodgkin's lymphoma (NHL)remain very high.
NHL is a radiosensitive tumor.
We hypothesize that targeted radioimmunotherapy combined with high-dose chemotherapy may increase response and survival rates in a safe and reliable manner.
Study Type
Interventional
Enrollment
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ahmed Galal, MD
- Phone Number: 31558 514-934-1934
- Email: galala@muhchem.mcgill.ca
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A1A1
- McGill University Health Center, Royal Victoria Hospital
-
Principal Investigator:
- Ahmed Galal, MD
-
Contact:
- Ahmed Galal, MD
- Phone Number: 31558 514-934-1934
- Email: galala@muhchem.mcgill.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >=18 to <=70 years
Relapsed or refractory Stage III or IV, grade 1,2, or 3 Follicular Lymphoma or transformed follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, or diffuse large B-Cell lymphoma as defined by the WHO and:
- Expressing the CD 20 antigen
- ECOG performance 0-2
- Written informed consent
- Prior collection of at least 2.5x10^6 CD34-positive peripheral blood stem cells/kg.
Exclusion Criteria:
- Abnormal renal function (Creatinine >2.5x upper limit of normal (ULN)
- Abnormal hepatic function (Bilirubin >2xULN, ALT/AST >3x ULN)
- Cardiac ejection fraction <40%
- Severe defects in pulmonary function tests (DLCO<70% predicted, FEV1, FVC<60% predicted) or receiving continuous oxygen
- A history of human anti-mouse antibodies (HAMA) or known type 1 hypersensitivity or anaphylactic proteins to any component of the Zevalin therapy.
- Female patients who are pregnant or breast feeding, and adults of reproductive potential who are not employing an effective method of birth control during study treatment
- Prior radiotherapy to >25% of the bone marrow or >20 Gy to critical organ (lung, liver, kidney, spinal cord).
- CNS lymphoma
- Ongoing infection
- Prior treatment with radioimmunotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Overall response rate
|
Secondary Outcome Measures
Outcome Measure |
---|
Survival Data, adverse events, molecular response
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ahmed Galal, MD, McGill University Health Center, Royal Victoria Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Study Registration Dates
First Submitted
February 20, 2007
First Submitted That Met QC Criteria
February 20, 2007
First Posted (Estimate)
February 22, 2007
Study Record Updates
Last Update Posted (Estimate)
February 27, 2007
Last Update Submitted That Met QC Criteria
February 26, 2007
Last Verified
February 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMA-05-017-ZEV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
University of NebraskaSchering-PloughCompletedNon-Hodgkins LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
Clinical Trials on Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )
-
Chulalongkorn UniversityBayerTerminatedDiffuse Large B-cell LymphomaThailand
-
M.D. Anderson Cancer CenterBiogenCompletedLymphoma, Mantle-CellUnited States
-
Spectrum Pharmaceuticals, IncBayerCompleted
-
BayerCompletedLymphoma, Follicular | Non-Hodgkin LymphomaBelgium
-
Soroka University Medical CenterUnknown
-
BayerCompletedLymphoma, Non-HodgkinBelgium, France, Spain, Italy, Canada, Switzerland, Netherlands, United Kingdom, Portugal, Germany, Sweden, Denmark, Norway
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 (PH1) | Primary HyperoxaluriaUnited States, France, United Kingdom, Israel, Germany
-
Alnylam PharmaceuticalsApproved for marketingPrimary HyperoxaluriaBelgium
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...United States
-
BayerCompletedNon-Hodgkin's Lymphoma (NHL)Japan